Mellissa J. Nixon

Mellissa J. Nixon

Auto-generated profile, based on publicly available information

Mellissa J. Nixon

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JGJennifer M. Giltnane
Jennifer M. Giltnane
KHKatherine E. Hutchinson
Katherine E. Hutchinson
TSThomas P. Stricker
Thomas P. Stricker
LFLuigi Formisano
Luigi Formisano
CYChristian D. Young
Christian D. Young
CACarlos L. Arteaga
Carlos L. Arteaga
Genomic profiling of ER + /HER2 − breast tumors after short-term estrogen deprivation revealed alterations associated with intrinsic resistance and provided mechanistic insights.

1 January 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
TWThomas A. Werfel
Thomas A. Werfel
DEDavid L. Elion
David L. Elion
BRBushra Rahman
Bushra Rahman
DHDonna J. Hicks
Donna J. Hicks
VSVioleta Sanchez
Violeta Sanchez
RCRebecca S. Cook
Rebecca S. Cook
Efferocytosis is the process by which apoptotic cells are cleared from tissue by phagocytic cells. The removal of apoptotic cells prevents them from undergoing secondary necrosis and releasing their inflammation-inducing intracellular contents. Efferocytosis also limits tissue damage by increasing immunosuppressive cytokines and leukocytes and maintains tissue homeostasis by promoting tolerance to antigens derived from apoptotic cells. Thus, tumor cell efferocytosis following cytotoxic cancer treatment could impart tolerance to tumor cells evading treatment-induced apoptosis with deleterious consequences in tumor residual disease. We report here that efferocytosis cleared apoptotic tumor cells in residual disease of lapatinib-treated HER2+ mammary tumors in MMTV-Neu mice, increased immunosuppressive cytokines, myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg). Blockade of efferocytosis induced secondary necrosis of apoptotic cells, but failed to prevent increased tumor MDSCs, Treg, and immunosuppressive cytokines. We found that efferocytosis stimulated expression of IFN-γ, which stimulated the expression of indoleamine-2,3-dioxegenase (IDO) 1, an immune regulator known for driving maternal-fetal antigen tolerance. Combined inhibition of efferocytosis and IDO1 in tumor residual disease decreased apoptotic cell- and necrotic cell-induced immunosuppressive phenotypes, blocked tumor metastasis, and caused tumor regression in 60% of MMTV-Neu mice. This suggests that apoptotic and necrotic tumor cells, via efferocytosis and IDO1, respectively, promote tumor ‘homeostasis’ and progression. Significance: These findings show in a model of HER2+ breast cancer that necrosis secondary to impaired efferocytosis activates IDO1 to drive immunosuppression and tumor progression.

21 August 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MAMargaret L. Axelrod
Margaret L. Axelrod
MNMellissa J. Nixon
Mellissa J. Nixon
PGPaula I. Gonzalez-Ericsson
Paula I. Gonzalez-Ericsson
RBRiley E. Bergman
Riley E. Bergman
MPMark A. Pilkinton
Mark A. Pilkinton
JBJustin M. Balko
Justin M. Balko
Purpose: The recent approval of anti-programmed death-ligand 1 immunotherapy in combination with nab-paclitaxel for metastatic triple-negative breast cancer (TNBC) highlights the need to understand the role of chemotherapy in modulating the tumor immune microenvironment (TIME).Experimental Design: We examined immune-related gene expression patterns before and after neoadjuvant chemotherapy (NAC) in a series of 83 breast tumors, including 44 TNBCs, from patients with residual disease (RD). Changes in gene expression patterns in the TIME were tested for association with recurrence-free (RFS) and overall survival (OS). In addition, we sought to characterize the systemic effects of NAC through single-cell analysis (RNAseq and cytokine secretion) of programmed death-1–high (PD-1HI) CD8+ peripheral T cells and examination of a cytolytic gene signature in whole blood.Results: In non-TNBC, no change in expression of any single gene was associated with RFS or OS, while in TNBC upregulation of multiple immune-related genes and gene sets were associated with improved long-term outcome. High cytotoxic T-cell signatures present in the peripheral blood of patients with breast cancer at surgery were associated with persistent disease and recurrence, suggesting active antitumor immunity that may indicate ongoing disease burden.Conclusions: We have characterized the effects of NAC on the TIME, finding that TNBC is uniquely sensitive to the immunologic effects of NAC, and local increases in immune genes/sets are associated with improved outcomes. However, expression of cytotoxic genes in the peripheral blood, as opposed to the TIME, may be a minimally invasive biomarker of persistent micrometastatic disease ultimately leading to recurrence.

15 January 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
DSDhivya R. Sudhan
Dhivya R. Sudhan
LSLuis J. Schwarz
Luis J. Schwarz
AGAngel Guerrero-Zotano
Angel Guerrero-Zotano
LFLuigi Formisano
Luigi Formisano
MNMellissa J. Nixon
Mellissa J. Nixon
CACarlos L. Arteaga
Carlos L. Arteaga
Purpose: The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater in patients with ER+/HER2+ tumors. We thus sought to discover mechanisms that may explain the benefit from extended adjuvant therapy with neratinib.Experimental Design: Mice with established ER+/HER2+ MDA-MB-361 tumors were treated with paclitaxel plus trastuzumab ± pertuzumab for 4 weeks, and then randomized to fulvestrant ± neratinib treatment. The benefit from neratinib was evaluated by performing gene expression analysis for 196 ER targets, ER transcriptional reporter assays, and cell-cycle analyses.Results: Mice receiving “extended adjuvant” therapy with fulvestrant/neratinib maintained a complete response, whereas those treated with fulvestrant relapsed rapidly. In three ER+/HER2+ cell lines (MDA-MB-361, BT-474, UACC-893) but not in ER+/HER2− MCF7 cells, treatment with neratinib induced ER reporter transcriptional activity, whereas treatment with fulvestrant resulted in increased HER2 and EGFR phosphorylation, suggesting compensatory reciprocal crosstalk between the ER and ERBB RTK pathways. ER transcriptional reporter assays, gene expression, and immunoblot analyses showed that treatment with neratinib/fulvestrant, but not fulvestrant, potently inhibited growth and downregulated ER reporter activity, P-AKT, P-ERK, and cyclin D1 levels. Finally, similar to neratinib, genetic and pharmacologic inactivation of cyclin D1 enhanced fulvestrant action against ER+/HER2+ breast cancer cells.Conclusions: These data suggest that ER blockade leads to reactivation of ERBB RTKs and thus extended ERBB blockade is necessary to achieve durable clinical outcomes in patients with ER+/HER2+ breast cancer.

31 March 2023
Verified
Other
Open access
MAMargaret L. Axelrod
Margaret L. Axelrod
MNMellissa J. Nixon
Mellissa J. Nixon
PGPaula I. Gonzalez-Ericsson
Paula I. Gonzalez-Ericsson
RBRiley E. Bergman
Riley E. Bergman
MPMark A. Pilkinton
Mark A. Pilkinton
JBJustin M. Balko
Justin M. Balko
Supplementary Figure 5: The change in sTILs during NAC is not prognostic for outcome in TNBC patients with residual disease.

31 March 2023
Verified
Other
Open access
TWThomas A. Werfel
Thomas A. Werfel
DEDavid L. Elion
David L. Elion
BRBushra Rahman
Bushra Rahman
DHDonna J. Hicks
Donna J. Hicks
VSVioleta Sanchez
Violeta Sanchez
RCRebecca S. Cook
Rebecca S. Cook
Supplemental Figure S5. Decreased tumor cellularity of tumors treated with the combination of lapatinib + BMS-777607 + epacadostat. Low power images of H&E-stained sections of tumors collected at treatment day 7. Arrows point to tumor cells, which stain darker purple, and which are evident as solid sheets in vehicle-treated samples, but only as pockets in the samples treated with lapatinib + BMS-777607 + Epacadostat. Asterisks represent areas of acellular debris.